References
- Apetoh> L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med.13, 1050–1059 (2007).
- Ronchetti A, Rovere P, Iezzi G et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol.163, 130–136 (1999).
- Rovere> P, Vallinoto C, Bondanza A et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol.161, 4467–4471 (1998).
- Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature392, 86–89 (1998).
- Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat. Immunol.2, 1010–1017 (2001).
- Ellerman JE, Brown CK, de Vera M et al. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res.13, 2836–2848 (2007).
- Rovere-Querini P, Capobianco A, Scaffidi P et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep.5, 825–830 (2004).
- Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med.202, 1691–1701 (2005).
- Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol.17, 359–365 (2005).
- Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev.220, 35–46 (2007).
- Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature418, 191–195 (2002).
- Gardella S, Andrei C, Ferrera D et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep.3, 995–1001 (2002).
- Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J. Intern. Med.255, 320–331 (2004).
- Palumbo R, Galvez BG, Pusterla T et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation. J. Cell Biol.179, 33–40 (2007).
- Messmer D, Yang H, Telusma G et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol.173, 307–313 (2004).
- Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest.108. 949–955 (2001).
- Orlova VV, Choi EY, Xie C et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J.26, 1129–1139 (2007).
- Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol.290, C917–C924 (2006).
- Yu M, Wang H, Ding A et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock26, 174–179 (2006).
- Beutler B, Jiang Z, Georgel P et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol.24, 353–389 (2006).
- Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med.13, 54–61 (2007).
- Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol.8, 487–496 (2007).
- Pisetsky DS. Autoimmunity: the nuclear arsenal of autoimmunity. Immunol. Cell Biol.85, 344–345 (2007).
- Galluzzi L, Maiuri MC, Vitale I et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ.14, 1237–1243 (2007).